Alopaeus Julia F, Hagesæther Ellen, Tho Ingunn
Department of Pharmacy, University of Oslo, 0316 Oslo, Norway.
Faculty of Health Sciences, OsloMet-Oslo Metropolitan University, N-0130 Oslo, Norway.
Pharmaceuticals (Basel). 2019 Jan 19;12(1):15. doi: 10.3390/ph12010015.
In this study, self-assembling Soluplus® micelles were examined for inherent properties. Through calorimetric analysis, the critical micelle concentration (CMC) could be determined at 25 and 37 °C, and the influence of three media (Milli-Q water, phosphate-buffered saline (PBS) with a pH of 7.4 and 0.1 M HCl) on the lower critical solution temperature (LCST) was detected. Furthermore, the solubilisation of a poorly soluble drug, furosemide, into the Soluplus® micelles was studied. The concentration-dependent properties of the micellar system were assessed through an examination of the micellar size, polydispersity, morphology, viscosity and solubilising properties, which were all found to be affected by the concentration, but temperature, pH and the composition of the test medium were also found to have an effect. Homogeneity in the estimated micellar size and morphology was shown for monophasic micelle dispersions in lower concentrations and with a shift towards more complex structures or aggregates in higher concentrations. The micelles were further investigated in terms of drug release and biocompatibility with mucus-producing HT29-MTX cells, where no biocompatibility issues were found. In this research, the implications for oral drug delivery are discussed and valuable preformulation information is provided on the micellar properties of a Soluplus® drug system in a liquid or semi-solid form.
在本研究中,对自组装的固体脂质纳米粒(Soluplus®)胶束的固有性质进行了研究。通过量热分析,可以测定25℃和37℃下的临界胶束浓度(CMC),并检测三种介质(超纯水、pH值为7.4的磷酸盐缓冲盐水(PBS)和0.1 M盐酸)对低临界溶液温度(LCST)的影响。此外,还研究了难溶性药物呋塞米在Soluplus®胶束中的增溶情况。通过检测胶束大小、多分散性、形态、粘度和增溶性质等胶束体系的浓度依赖性性质,发现这些性质均受浓度影响,但温度、pH值和测试介质的组成也有影响。较低浓度下单相胶束分散体的估计胶束大小和形态具有均一性,而较高浓度下则向更复杂的结构或聚集体转变。进一步研究了胶束的药物释放以及与产生黏液的HT29-MTX细胞的生物相容性,未发现生物相容性问题。在本研究中,讨论了其对口服给药的意义,并提供了关于液体或半固体形式的Soluplus®药物体系胶束性质的有价值的处方前信息。